Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creatine phosphate, levosimendan, and recombinant human brain natriuretic peptide for chronic heart failure
ChiCTR-IPR-15006512Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jun 2015
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of creatine phosphate, levosimendan and nesiritide in chronic heart failure (CHF) (4 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Galectin-3, copeptin and 2 more. Started Jun 2015; status: recruiting.
02
Drugs
creatine phosphatelevosimendannesiritide
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on ChiCTR-IPR-15006512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006512.